Richard Francis, Teva CEO
Teva says it's actively searching for late-stage programs in next phase of growth strategy
Teva Pharmaceuticals is looking to build out its pipeline as its “pivot to growth” strategy begins to take shape, CEO Richard Francis said on the company’s earnings call.
The generics giant has been investing heavily in R&D, with an emphasis on Phase III programs in asthma and schizophrenia. When it comes to new deals, Francis is particularly interested in late-stage or early commercial assets. And he now has more firepower, thanks to a $500 million upfront payment from Teva’s recent anti-TL1A deal with Sanofi.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
